Tag: myelodysplastic syndrome

1. Luspatercept may significantly reduce transfusion burden in patients with lower-risk myelodysplastic syndromes with ring sideroblasts for whom erythropoiesis-stimulating agents have not been effective. Evidence Rating: 1 (Excellent) Myelodysplastic syndromes are acquired bone marrow disorders characterized by ineffective hematopoiesis, progressive cytopenias and an increased risk of acute myeloid leukemia, predominantly seen in...
1. Luspatercept may significantly reduce transfusion burden in patients with lower-risk myelodysplastic syndromes with ring sideroblasts for whom erythropoiesis-stimulating agents have not been effective. Evidence Rating: 1 (Excellent) Myelodysplastic syndromes are acquired bone marrow disorders characterized by ineffective hematopoiesis, progressive cytopenias and an increased risk of acute myeloid leukemia, predominantly seen in...
The association of depression with subsequent dementia diagnosis: A Swedish nationwide cohort study from 1964 to 2016 1. There is a significantly increased risk of dementia in patients with previously diagnosed depression, with the highest risk observed in patients diagnosed with severe depression Evidence Level: 2 (Good) The prevalence of dementia is on...
1. TP53 mutant status significantly associated with bone marrow blast clearance after treatment with decitabine in patients with acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS). Evidence Rating Level: 2 (good) ­ Study Rundown: AML and MDS are clonal myeloid neoplasms. Decitabine is a hypomethylating agent that promotes re-expression of tumor...
1. Germline transmission of a mutation in ETV6 was identified in three distinct families presenting with myelodysplastic syndrome (thrombocytopenia and hematologic malignancy) inherited in autosomal dominant fashion. 2. In addition to myelodysplastic syndrome, patients with ETV6 mutations were also affected by a diverse set of malignancies including skin and colon...
Image: PD 1. Adding entinostat to azacitidine (AZA) therapy for myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) with myelodysplasia-related changes does not improve rates of hematologic normalization (HN). 2. Increased duration of AZA therapy increases HN rate compared to standard dosing. Evidence Rating Level: 1 (Excellent) Study Rundown: Previous trials have...